A genomic mutation signature predicts the clinical outcomes of immunotherapy and characterizes immunophenotypes in gastrointestinal cancer
Abstract The association between genetic variations and immunotherapy benefit has been widely recognized, while such evidence in gastrointestinal cancer remains limited. We analyzed the genomic profile of 227 immunotherapeutic gastrointestinal cancer patients treated with immunotherapy, from the Mem...
Main Authors: | Xi Jiao, Xin Wei, Shuang Li, Chang Liu, Huan Chen, Jifang Gong, Jian Li, Xiaotian Zhang, Xicheng Wang, Zhi Peng, Changsong Qi, Zhenghang Wang, Yujiao Wang, Yanni Wang, Na Zhuo, Henghui Zhang, Zhihao Lu, Lin Shen |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2021-05-01
|
Series: | npj Precision Oncology |
Online Access: | https://doi.org/10.1038/s41698-021-00172-5 |
Similar Items
-
Alterations in DNA damage response and repair genes as potential biomarkers for immune checkpoint blockade in gastrointestinal cancer
by: Yujiao Wang, et al.
Published: (2022-08-01) -
Serological biomarkers predict immune-related adverse events and clinical benefit in patients with advanced gastrointestinal cancers
by: Yanni Wang, et al.
Published: (2022-09-01) -
Helicobacter pylori and immunotherapy for gastrointestinal cancer
by: Keren Jia, et al.
Published: (2024-03-01) -
Combination of AKT1 and CDH1 mutations predicts primary resistance to immunotherapy in dMMR/MSI-H gastrointestinal cancer
by: Hui Chen, et al.
Published: (2022-06-01) -
Current Status and Future Perspective of Immunotherapy in Gastrointestinal Cancers
by: Zhihao Lu, et al.
Published: (2020-08-01)